Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swedish (OMX) Biotech Industry Analysis

UpdatedFeb 25, 2026
DataAggregated Company Financials
Companies49
  • 7D-0.5%
  • 3M6.0%
  • 1Y4.3%
  • YTD10.4%

Over the last 7 days, the Biotech industry has remained flat, although notably Bonesupport Holding gained 6.7%. The past year has been better, since the industry has gained 4.3% in that time. As for the next few years, earnings are expected to grow by 27% per annum.

Industry Valuation and Performance

Has the Swedish Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 25 Feb 2026SEK 228.0bSEK 38.9b-SEK 5,311,752,067.1317.7x-42.9x5.9x
Fri, 23 Jan 2026SEK 227.7bSEK 38.1b-SEK 556,115,492.0038.9x-409.4x6x
Sun, 21 Dec 2025SEK 205.1bSEK 38.1b-SEK 556,521,419.3732x-368.6x5.4x
Tue, 18 Nov 2025SEK 206.2bSEK 37.4b-SEK 1,245,320,091.9338.5x-165.6x5.5x
Thu, 16 Oct 2025SEK 200.9bSEK 36.4bSEK 3.1b31.2x64.9x5.5x
Sat, 13 Sep 2025SEK 190.9bSEK 36.4bSEK 3.0b29.5x63.1x5.2x
Mon, 11 Aug 2025SEK 186.9bSEK 35.9bSEK 2.8b27.4x67x5.2x
Wed, 09 Jul 2025SEK 186.1bSEK 35.2bSEK 2.3b29.7x80.9x5.3x
Fri, 06 Jun 2025SEK 195.9bSEK 35.2bSEK 2.2b30.4x88.5x5.6x
Sun, 04 May 2025SEK 193.5bSEK 34.0bSEK 835.9m30.3x231.5x5.7x
Tue, 01 Apr 2025SEK 185.6bSEK 33.7bSEK 724.7m31.7x256.1x5.5x
Thu, 27 Feb 2025SEK 213.3bSEK 33.3bSEK 478.3m43.9x445.9x6.4x
Sat, 25 Jan 2025SEK 222.3bSEK 33.1b-SEK 4,401,281,598.69141.9x-50.5x6.7x
Mon, 23 Dec 2024SEK 215.0bSEK 33.0b-SEK 4,423,168,415.46155.2x-48.6x6.5x
Wed, 20 Nov 2024SEK 205.9bSEK 33.0b-SEK 4,537,843,621.72137.3x-45.4x6.2x
Fri, 18 Oct 2024SEK 210.0bSEK 31.4b-SEK 5,536,559,250.4548.4x-37.9x6.7x
Sun, 15 Sep 2024SEK 218.6bSEK 31.5b-SEK 5,518,169,191.2152.2x-39.6x6.9x
Tue, 13 Aug 2024SEK 193.4bSEK 31.4b-SEK 5,421,984,283.7443.2x-35.7x6.2x
Thu, 11 Jul 2024SEK 197.9bSEK 30.6b-SEK 5,535,018,222.9139.2x-35.7x6.5x
Sat, 08 Jun 2024SEK 196.5bSEK 30.6b-SEK 5,437,395,463.7739.3x-36.1x6.4x
Mon, 06 May 2024SEK 184.9bSEK 31.0b-SEK 5,452,001,822.3550.4x-33.9x6x
Wed, 03 Apr 2024SEK 181.8bSEK 29.8b-SEK 5,279,670,051.7960x-34.4x6.1x
Fri, 01 Mar 2024SEK 176.3bSEK 29.8b-SEK 5,643,835,580.8354.2x-31.2x5.9x
Sun, 28 Jan 2024SEK 187.5bSEK 28.7b-SEK 1,215,639,777.0060.8x-154.2x6.5x
Tue, 26 Dec 2023SEK 181.8bSEK 28.7b-SEK 1,195,731,362.0060.6x-152x6.3x
Thu, 23 Nov 2023SEK 169.0bSEK 28.7b-SEK 1,186,816,677.0055.6x-142.4x5.9x
Sat, 21 Oct 2023SEK 150.7bSEK 27.4b-SEK 2,006,137,043.0048.1x-75.1x5.5x
Mon, 18 Sep 2023SEK 154.2bSEK 27.4b-SEK 1,977,805,956.0050.6x-78x5.6x
Wed, 16 Aug 2023SEK 157.6bSEK 27.6b-SEK 1,574,468,715.0052.5x-100.1x5.7x
Fri, 14 Jul 2023SEK 158.2bSEK 26.4b-SEK 1,342,139,251.0045x-117.9x6x
Sun, 11 Jun 2023SEK 171.7bSEK 26.4b-SEK 1,234,687,020.0045.9x-139.1x6.5x
Tue, 09 May 2023SEK 180.8bSEK 26.3b-SEK 1,155,825,576.0046.1x-156.5x6.9x
Thu, 06 Apr 2023SEK 168.1bSEK 25.4b-SEK 2,017,740,646.0038.1x-83.3x6.6x
Sat, 04 Mar 2023SEK 173.6bSEK 25.4b-SEK 2,050,586,620.0040.2x-84.7x6.8x
Price to Earnings Ratio

-84.7x


Total Market Cap: SEK 173.6bTotal Earnings: -SEK 2,050,586,620.00Total Revenue: SEK 25.4bTotal Market Cap vs Earnings and Revenue0%0%0%
Swedish Biotech Industry Price to Earnings3Y Average -49.2x202420252026
Current Industry PE
  • Investors are relatively neutral on the Swedish Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 6.0x.
Past Earnings Growth
  • The earnings for companies in the Biotechs industry have deteriorated over the last three years.
  • Meanwhile revenues for these companies have grown 15% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.

Industry Trends

Which industries have driven the changes within the Swedish Healthcare industry?

SE Market1.61%
Healthcare0.03%
Biotech-0.50%
Biotech-0.50%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
BONEX Bonesupport HoldingSEK 197.5011.5%
+SEK 1.3b		-48.8%PE85.6x
BIOG B BioGaiaSEK 107.704.5%
+SEK 465.3m		-15.0%PE32.7x
VITR VitrolifeSEK 90.552.5%
+SEK 304.7m		-53.5%PS3.6x
HAMLET B Hamlet BioPharmaSEK 4.2014.3%
+SEK 93.3m		1.4%PS4191x
ISOFOL Isofol MedicalSEK 0.8848.7%
+SEK 80.5m		-46.6%PB2.3x

Latest News

BIOA B
SEK 318.20
BioArctic
7D
-12.7%
1Y
31.9%
ISOFOL
SEK 0.88
Isofol Medical
7D
48.7%
1Y
-46.6%
DMYD B
SEK 15.64
Diamyd Medical
7D
-5.4%
1Y
-0.5%
SOBI
SEK 404.60
Swedish Orphan Biovitrum
7D
-3.9%
1Y
29.1%

Pipeline And Margin Risks Will Challenge Rare Disease Expansion Narrative

Catalysts About Swedish Orphan Biovitrum Swedish Orphan Biovitrum focuses on rare disease medicines across hematology, immunology and specialty care. What are the underlying business or industry changes driving this perspective?
BONEX
SEK 197.50
Bonesupport Holding
7D
11.5%
1Y
-48.8%

BONEX: De Novo Shift Will Support Long Term Upside Potential

Analysts have slightly trimmed their fair value estimate for Bonesupport Holding to SEK370.6, from SEK374.6, reflecting minor adjustments to the discount rate, revenue growth, profit margin and future P/E assumptions, while keeping the overall thesis broadly intact. What's in the News Bonesupport issued earnings guidance for Q4 2025, with net sales expected at 313 MSEK at constant exchange rates, based on company guidance for that period (company guidance).
CRNO B
SEK 6.54
Cereno Scientific
7D
1.9%
1Y
25.6%
FLUO
SEK 35.50
FluoGuide
7D
6.3%
1Y
-22.5%
ONCO
SEK 1.79
Oncopeptides
7D
-34.8%
1Y
-4.1%
CANTA
SEK 4.59
Cantargia
7D
-9.4%
1Y
170.2%
BIOG B
SEK 107.70
BioGaia
7D
4.5%
1Y
-15.0%

BIOG B: Dividend Reset And Solid Margins Will Support Higher Future Earnings Multiple

Analysts have kept their SEK 140.0 price target for BioGaia broadly unchanged, citing slightly higher assumed discount rates and a modestly lower profit margin outlook. These factors are largely offset by stable long term growth and P/E expectations.
HNSA
SEK 32.74
Hansa Biopharma
7D
-6.0%
1Y
30.2%
MVIR
SEK 1.29
Medivir
7D
-11.6%
1Y
-32.5%
VITR
SEK 90.55
Vitrolife
7D
2.5%
1Y
-53.5%

VITR: Restructuring Of Genetic Services Will Drive Future Upside Potential

Analysts have trimmed their price target on Vitrolife to €176.75 from €187, reflecting updated assumptions that include a higher discount rate, a higher future P/E multiple, and revised expectations for revenue growth and profit margins. What's in the News Vitrolife plans to record a goodwill impairment of SEK 5.4b in the fourth quarter of 2025, linked to the Igenomix acquisition (Key Developments).
BINV
SEK 26.30
BioInvent International
7D
2.1%
1Y
7.6%

We're Not Very Worried About BioInvent International's (STO:BINV) Cash Burn Rate

Jan 26
We're Not Very Worried About BioInvent International's (STO:BINV) Cash Burn Rate
SANION
SEK 22.90
Saniona
7D
-8.4%
1Y
184.5%
HAMLET B
SEK 4.20
Hamlet BioPharma
7D
14.3%
1Y
1.4%